A study on the public health and socioeconomic impact of substandard and falsified medical products, showed that 10% of ...

A generic product cannot enter the market until the originator product’s IP has expired, but the development process can take ...

Lupin Limited today announced that it has received tentative approval from the United States Food and Drug Administration for ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Mumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food ...

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg. This product would be ...

Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus.

Alkem Laboratories announced the launch of generic empagliflozin and its combinations in India under the brand name Empanorm at prices that are approximately 80% lower than the innovator products.

Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over ...

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.